Almirall, S.A.
TypeSociedad Anónima
BMAD: ALM
ISINES0157097017
Founded1943
FounderAntonio Gallardo Carreras
Headquarters
Ronda del General Mitre, 151
08022 Barcelona
Spain
Area served
International
ProductsEbastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, Actikerall.[1]
RevenueIncrease €855.339 million (2019)[2]
Increase €105.909 million (2019)[2]
Total assetsIncrease €2.439 billion (2019)[2]
Number of employees
Decrease 1,773 (2019)[2]
Websitewww.almirall.com

Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[3]

In 2016, it generated total revenue of €859.3 million[4] and became the leading pharmaceutical company in R&D investment in Spain.

With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and United States.

History

Vial containing cloperastine fendizoate produced by Almirall.

Early history

Almirall SA was founded in 1943 in Spain. In 1979, the company launched gastroprokinetic clebopride in Spain, the first product from the company’s internal R&D team. In 1984, the business launched antacid product, almagate, in Spain, as well as anti-inflammatory piketoprofen in 1985 and antihistamine ebastine and cinitapride in 1985. In the same year, Almirall opened its first subsidiary, based in Belgium. In 1992 the company launched aceclofenac and a year later opened its second foreign subsidiary, in Portugal. The company's new headquarters were opened in Barcelona, in 1994. In 1997 Almirall and Prodesfarma merged their interests.

Further expansion

In 2000 the FDA approved anti-migraine agent almotriptan. A year later the company opened its Mexican subsidiary as well as acquiring its French affiliate. Beginning in 2002, Almirall opened a series of European based subsidiaries; Italy (2002), Germany (2003), Austria, Poland, the United Kingdom, Ireland and Switzerland (2008) and Nordic Countries (2010).[5]

In 2005 the business acquired the commercial rights for Sativex in Europe for the treatment of spasticity associated to multiple sclerosis. In 2006, the company opened its new R&D Centre based in Sant Feliu de Llobregat as well as the acquisition of the Centre of Excellence for Inhalation Technology.

In 2007, the company floated on the Spanish stock market, as well as acquiring European dermatology specialist, Hermal. The company also acquired a portfolio of eight products from Shire plc.

In 2011, Almirall launched Actikerall prescribed for the local treatment of actinic keratosis.

In 2012, Almirall opened its first North America subsidiary, based in Canada[5] and launched aclidinium, prescribed for chronic obstructive pulmonary disease (COPD), in Europe under the brand Eklira Genuair and Bretaris Genuair and in the United States under the brand Tudorza Pressair. The business also launched Monovo, for the treatment of inflammatory skin diseases such as psoriasis.

In 2013 Almirall acquired another specialist dermatology company, Aqua Pharmaceuticals. The company launched linaclotide in Europe (Constella) for irritable bowel syndrome with constipation (IBS-C) and opened its Netherlands subsidiary.[5]

In 2014 Almirall divested its rights to its respiratory franchise to Astrazeneca focussing on the dermatology, later in 2015 declaring its strategic intention to become a leading pharmaceutical company in the field of dermatology and continuing with its expansion by acquiring Poli Group Holding.

In 2016 Almirall acquired ThermiGen LLC.[6]

In January 2020, the company announced it would acquire Bioniz Therapeutic.[7][8] In 2020, Almirall earned 74.3 million euros, 30% less than the previous year. The following year it closed with a loss of 40.9 million. According to the annual accounts, the losses were justified by the accounting impairment of various products, although sales grew by 2.5%, driven by the dermatology business. In February 2022 it was announced that Carlos Gallardo would replace his father, Jorge Gallardo, as president of the company.[9]

Activities

Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona[10] in Spain. Highlighted among the international alliances are those with the Imperial College London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation.[11] In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).

Almirall chemical plant near Sant Celoni, Spain.

Centres

The company has three R&D centres distributed in Spain and Germany (Reinbek) and Switzerland (Lugano). The R&D centre in Sant Feliu de Llobregat (Barcelona), houses the departments involved in all stages of R&D, as well as the development of new chemical entities. The Reinbek Centre of Excellence for Dermatology specializes in the development of new formulas for the treatment of skin diseases.

The company also has three production centres: two in Spain, the pharmaceutical plant in Sant Andreu de la Barca (Barcelona) and the pharmaceutical and chemical plant in Sant Celoni (Barcelona); and a pharmaceutical plant in Germany (Reinbek); as well as 13 affiliates in Germany, Austria, Belgium-Luxembourg, the United States, France, the Netherlands, Italy, the Nordic countries, Poland, Portugal, the United Kingdom-Ireland, Spain and Switzerland.[12]

Numbers

20102011201220132014 [13]2015 [14]2016 [4]
Total revenue€1002,1 MM€873,1 MM€900,2 MM€825,5 MM€1.407,4 MM€769 MM€859,3 MM
Net sales€882.4 MM€768.4 MM€682.9 MM€692.9 MM€786.4 MM€685 MM€764,4 MM
% International sales-50%60%62%70%68%70%
% Sales of own medicines--59%64%70%67%77%
Investment in R&D [15]16.4% of net sales18.8% of net sales23.4% of net sales18% of net sales12.8% of net sales9.7% of net sales12,9% of net sales
Employees2,8312,7652,8713,0002,1001,8891,975
Affiliates13131415141313
R&D Centres [16]3333223
Production centres3333223

Main products

BrandActive ingredientPathology
EbastelEbastineAllergy
MonodoxDoxycyclineSevere Acne
ActiclateDoxycycline hyclateSevere Acne
AlmogranAlmotriptanMigraine
Tesavel and EfficibSitagliptin and sitagliptin/metforminDiabetes
SolarazeDiclofenac sodiumActinic keratosis
AirtalAceclofenacMusculoskeletal pain
DecodermFluprednideneFungal dermatitis
CordranFludroxycortideInflammation and itching of the skin
ParapresCandesartanHypertension
AlmaxAlmagateAcidity
BalneumUreaDry skin
CleborilCleboprideGastroesophageal reflux disease
Actikerall5-Fluorouracil / salicylic acidActinic keratosis
SativexNabiximolsSpasticity in Multiple Sclerosis
MonovoMometasonePsoriasis
IlumetriTildrakizumabPsoriasis

References

  1. ↑ Products «Products of Almirall S.A. Archived 5 September 2014 at the Portuguese Web Archive» Retrieved 17 December 2014
  2. 1 2 3 4 "Almirall Annual Report 2019". Almirall. Archived from the original on 2 August 2021. Retrieved 1 December 2020.
  3. ↑ "Almirall | About Almirall | History". www.almirall.com. Archived from the original on 29 September 2018. Retrieved 31 May 2023.
  4. 1 2 www.almirall.com (PDF) https://www.almirall.com/documents/10876/201201/170224_FY16_FR_English.pdf. Retrieved 31 May 2023. {{cite web}}: Missing or empty |title= (help)
  5. 1 2 3 "Archived copy". www.almirall.com. Archived from the original on 2 August 2021. Retrieved 31 May 2023.{{cite web}}: CS1 maint: archived copy as title (link)
  6. ↑ "Almirall Closes The Acquisition Of ThermiGen LLC Entering The Aesthetics Market". BioSpace. Archived from the original on 2 March 2023. Retrieved 2 March 2023.
  7. ↑ "Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology".
  8. ↑ "Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases".
  9. ↑ Moreno Gené, Josep (9 July 2021). "El derecho del otro progenitor al disfrute del permiso por nacimiento de hijo reconocido en Convenio colectivo tras la entrada en vigor del Real Decreto-ley 6/2019. A propósito de la STS de 27 de enero de 2021". IUSLabor. Revista d'anàlisi de Dret del Treball (2): 288–315. doi:10.31009/iuslabor.2021.i2.10. hdl:10459.1/72762. ISSN 1699-2938. S2CID 243137601.
  10. ↑ "Home". Parc Científic de Barcelona (in Catalan). 10 August 2020. Archived from the original on 10 May 2023. Retrieved 31 May 2023.
  11. ↑ "Esborrany automàtic – BRN" (in Catalan). Archived from the original on 26 March 2023. Retrieved 31 May 2023.
  12. ↑ "Almirall Media | FAQs". www.almirall.com. Archived from the original on 26 October 2016. Retrieved 31 May 2023.
  13. ↑ "Archived copy" (PDF). www.almirall.com. Archived (PDF) from the original on 9 March 2016. Retrieved 31 May 2023.{{cite web}}: CS1 maint: archived copy as title (link)
  14. ↑ "Archived copy" (PDF). www.almirall.com. Archived (PDF) from the original on 17 June 2016. Retrieved 31 May 2023.{{cite web}}: CS1 maint: archived copy as title (link)
  15. ↑ Partnering and Collaboration «Partnering and Collaboration Archived 5 September 2014 at the Portuguese Web Archive» Retrieved 18 December 2014
  16. ↑ R&D in Key Therapeutic Areas «R&D in Key Therapeutic Areas Archived 18 December 2014 at archive.today» Retrieved 18 December 2014
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.